Viewing Study NCT04950894


Ignite Creation Date: 2025-12-25 @ 1:43 AM
Ignite Modification Date: 2025-12-26 @ 12:01 AM
Study NCT ID: NCT04950894
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-05-01
First Post: 2021-06-18
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation
Sponsor: LivaNova
Organization:

Study Overview

Official Title: Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Neurostimulation
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: OSPREY
Brief Summary: Multi-center, open-label, prospective, randomized clinical trial of the aura6000(R) System for the reduction of apnea and hypopneas in adult patients with moderate to severe obstructive sleep apnea who have failed or are unwilling to use positive airway pressure treatment.
Detailed Description: All qualifying subjects will be implanted. Subjects will be randomized 2:1 in favor of Stimulation therapy (Active Group). Randomization will occur following implant and prior to the Month 1 visit.

The Active group will start Stimulation therapy at Month 1. The Control group may continue with their current sleep apnea treatment until Month 7, and will receive Stimulation therapy beginning at Month 7 +1Day. (All subjects are excluded from use of PAP or surgical treatments after enrollment through Month 13)

Safety and efficacy will be evaluated at Month 7, and again at Month 13.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: True
Is an Unapproved Device?: True
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: